MTOR and prostate carcinoma: In a study of prostate cancer cell lines, mTOR inhibitors enhanced GAS5 transcript levels in androgen-sensitive but not in androgen-independent cell lines, which exhibit especially low levels of endogenous GAS5 lncRNA.